



National Center
for Advancing
Translational Sciences

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

**Joint Meeting of the
National Center for Advancing Translational Sciences Advisory Council
(5th Meeting) and Cures Acceleration Network Review Board (6th
Meeting)**

January 16, 2014

8:30 a.m. - 5:00 p.m.

Building 31C, 6th Floor, Conference Room 10
Bethesda, Maryland 20892

FUTURE COUNCIL and CAN BOARD MEETINGS

2014

January 16
May 16
September 19

2015

January 15-16
May 21-22
September 24-25

CAN Board only (by phone)

December 11

December 12

Agenda – OPEN SESSION

Open Session of the meeting will be webcast. To view, please go to: <http://videocast.nih.gov/summary.asp?live=13505>

8:30 - 8:50 a.m.

CALL TO ORDER, OPEN SESSION

Christopher P. Austin, M.D.
Director, NCATS
Chairperson - Advisory Council

Freda Lewis-Hall, M.D.
Chief Medical Officer, Pfizer
Chairperson - CAN Board

8:50 - 9:00 a.m.

Approval of Minutes of 4th Joint Meeting

**Confirmation of Dates for Future NCATS Advisory Council/CAN
Review Board Meetings**

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

9:00 - 10:00 a.m.

NCATS DIRECTOR'S REPORT

Christopher P. Austin, M.D., Director, NCATS

Discussion

10:00 - 10:30 a.m.	BREAK
10:30 - 11:15 a.m.	<p>CAN Review Board Report on Other Transactions</p> <p>Freda Lewis-Hall M.D., Chief Medical Officer, Pfizer</p> <p>Discussion</p>
11:15 a.m. - Noon	<p>Project Opportunity/Need Analyses in Translational Science</p> <p>Christopher P. Austin, M.D., Director, NCATS</p> <p>Discussion</p>
Noon - 1:00 p.m.	LUNCH
1:00 - 1:45 p.m.	<p>Rare Diseases: Then and Now – 30 Years of Advancements</p> <p>Stephen Groft, Pharm.D., Director, ORDR, NCATS</p> <p>Discussion</p>
1:45 - 2:15 p.m.	<p>Pediatric Study-Researcher Matching</p> <p>W. Charles Huskins, M.D., M.Sc., Professor of Pediatrics, Mayo Clinic</p> <p>Discussion</p>
2:15 - 2:45 p.m.	<p>REPORT FROM COUNCIL SUBCOMMITTEES</p> <ul style="list-style-type: none"> • Patient engagement • Partnerships with pharmaceutical and biotechnology companies and venture capital firms • Medical technologies (devices and diagnostics) <p>Discussion</p>
2:45 - 3:00 p.m.	<p>Concept Clearance</p> <p>Platform Delivery Technologies for Nucleic Acid Therapeutics</p> <p>P.J. Brooks, Ph.D., Health Scientist Administrator, ORDR, NCATS</p>

3:00 p.m.

ADJOURN, OPEN SESSION

3:15 - 5:00 p.m.

CLOSED SESSION

This portion of the meeting is closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

Review of Conflict of Interest, Confidentiality and Council Procedures

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

Council Consideration of Pending Applications

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council